Medical Research
(H30)
IRS Verified
DX Registered
990 on File
D-FEET CANCER THE DALTON FOX FOUNDATION
Financial strength (30%)
84/100
Reliability (20%)
45/100
Effectiveness (25%)
68/100
Impact (25%)
60/100
CharityAI™ Score
Not yet evaluated
Mission Statement
D-Feet Cancer The Dalton Fox Foundation raises awareness of Ewing Sarcoma and other under-studied pediatric cancers. By directly funding research into these cancers, we are determined to help discover more effective and less toxic treatments while supporting both patients and families during their greatest time of need.
Financial Overview — FY 2024
$200K
Total Revenue
$180K
Total Expenses
N/A
Net Assets
N/A
Employees
Revenue Sources
Program Expense Ratio
N/A
Fundraising Efficiency
13.3%
Operating Reserve
N/A
Liability-to-Asset
0.0%
Revenue Diversification
N/A
Executive Compensation
$0
Compared with Peers
FY 2023
Compared with 1,004 similar organizations
(United States, Medical Research, $100K–$1M in expenses), FY 2023.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
87.1% | 86.3% |
P10P90
|
Above median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
4.4% | 10.6% |
P10P90
|
Above median |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
8.5% | 0.0% |
P10P90
|
Bottom quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
17.7 mo | 13.1 mo |
P10P90
|
Above median |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
0.4% | 0.3% |
P10P90
|
Below median |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
78.2% | 95.3% |
P10P90
|
Above median |
|
Revenue growth
Year over year revenue growth
|
24.4% | 4.8% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
404.0% | 12.9% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
27.6% | -0.2% |
P10P90
|
Impact
1 program| Outcome / Program | People Served | Cost / Service | # Completed | Duration |
|---|---|---|---|---|
| Targeted pediatric cancer treatments | 300 | $500.00 | — | Lifetime |
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2024 | $200K | $180K | N/A | — | — |
| 2023 | $197K | $143K | $211K | 87.1% | 0 |
| 2022 | $159K | $28K | $156K | 11.7% | 0 |
| 2021 | $95K | $31K | N/A | — | 0 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.